NO990857L - Fosfinsyreamider som matriks-metallprotease-inhibitorer - Google Patents

Fosfinsyreamider som matriks-metallprotease-inhibitorer

Info

Publication number
NO990857L
NO990857L NO990857A NO990857A NO990857L NO 990857 L NO990857 L NO 990857L NO 990857 A NO990857 A NO 990857A NO 990857 A NO990857 A NO 990857A NO 990857 L NO990857 L NO 990857L
Authority
NO
Norway
Prior art keywords
acid amides
protease inhibitors
phosphinic acid
matrix metal
metal protease
Prior art date
Application number
NO990857A
Other languages
English (en)
Norwegian (no)
Other versions
NO990857D0 (no
Inventor
Stanislaw Pikul
Kelly Lynn Mcdow-Dunham
Biswanath De
Yetunde Olabisi Taiwo
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of NO990857D0 publication Critical patent/NO990857D0/no
Publication of NO990857L publication Critical patent/NO990857L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/36—Amides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576—Six-membered rings
    • C07F9/58—Pyridine rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms
    • C07F9/655345—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having sulfur atoms, with or without selenium or tellurium atoms, as the only ring hetero atoms the sulfur atom being part of a five-membered ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO990857A 1996-08-28 1999-02-23 Fosfinsyreamider som matriks-metallprotease-inhibitorer NO990857L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2476596P 1996-08-28 1996-08-28
PCT/US1997/014556 WO1998008853A1 (en) 1996-08-28 1997-08-22 Phosphinic acid amides as matrix metalloprotease inhibitors

Publications (2)

Publication Number Publication Date
NO990857D0 NO990857D0 (no) 1999-02-23
NO990857L true NO990857L (no) 1999-04-28

Family

ID=21822291

Family Applications (1)

Application Number Title Priority Date Filing Date
NO990857A NO990857L (no) 1996-08-28 1999-02-23 Fosfinsyreamider som matriks-metallprotease-inhibitorer

Country Status (27)

Country Link
US (1) US5830915A (de)
EP (1) EP0925303B1 (de)
JP (1) JP3539736B2 (de)
KR (1) KR20000035925A (de)
CN (1) CN1228780A (de)
AR (1) AR009357A1 (de)
AT (1) ATE226590T1 (de)
AU (1) AU732653B2 (de)
BR (1) BR9713182A (de)
CA (1) CA2264254C (de)
CO (1) CO4900033A1 (de)
CZ (1) CZ63699A3 (de)
DE (1) DE69716619T2 (de)
DK (1) DK0925303T3 (de)
HU (1) HUP9903916A3 (de)
ID (1) ID18145A (de)
IL (1) IL128668A (de)
NO (1) NO990857L (de)
NZ (1) NZ334258A (de)
PE (1) PE107698A1 (de)
PL (1) PL331854A1 (de)
RU (1) RU2170232C2 (de)
SK (1) SK25499A3 (de)
TR (1) TR199900399T2 (de)
TW (1) TW518338B (de)
WO (1) WO1998008853A1 (de)
ZA (1) ZA977700B (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030206874A1 (en) * 1996-11-21 2003-11-06 The Proctor & Gamble Company Promoting whole body health
KR100352316B1 (ko) * 1997-07-31 2002-09-12 더 프록터 앤드 갬블 캄파니 메탈로프로테아제억제제로서사용되는술포닐아미노치환히드록삼산유도체
US6846478B1 (en) 1998-02-27 2005-01-25 The Procter & Gamble Company Promoting whole body health
DE19850072A1 (de) * 1998-10-30 2000-05-04 Bayer Ag Phosphinat-Peptidanaloga zur Behandlung von fibrotischen Erkrankungen
US6313123B1 (en) 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
US6277885B1 (en) 1999-01-27 2001-08-21 American Cyanamid Company Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6200996B1 (en) 1999-01-27 2001-03-13 American Cyanamid Company Heteroaryl acetylenic sulfonamide and phosphinic acid amide hydroxamic acid tace inhibitors
US6753337B2 (en) 1999-01-27 2004-06-22 Wyeth Holdings Corporation Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase/tace inhibitors
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
CN1178915C (zh) 1999-01-27 2004-12-08 惠氏控股有限公司 含有炔基的异羟肟酸衍生物、其制备及其作为基质金属蛋白酶抑制剂/TNF-α转变酶抑制剂的用途
US6762178B2 (en) 1999-01-27 2004-07-13 Wyeth Holdings Corporation Acetylenic aryl sulfonamide and phosphinic acid amide hydroxamic acid TACE inhibitors
US6326516B1 (en) 1999-01-27 2001-12-04 American Cyanamid Company Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors
DE60012302T2 (de) * 1999-01-27 2005-08-04 Wyeth Holdings Corp. Acetylenische arylsulfonamid- und phosphinsäureamid-hydroxamsäure-derivate als tace inhibitoren
US6340691B1 (en) 1999-01-27 2002-01-22 American Cyanamid Company Alkynyl containing hydroxamic acid compounds as matrix metalloproteinase and tace inhibitors
US6946473B2 (en) 1999-01-27 2005-09-20 Wyeth Holdings Corporation Preparation and use of acetylenic ortho-sulfonamido and phosphinic acid amido bicyclic heteroaryl hydroxamic acids as TACE inhibitors
AR035313A1 (es) * 1999-01-27 2004-05-12 Wyeth Corp Inhibidores de tace acetilenicos de acido hidroxamico de sulfonamida a base de alfa-aminoacidos, composiciones farmaceuticas y el uso de los mismos para la manufactura de medicamentos.
PL350340A1 (en) 1999-03-03 2002-12-02 Procter & Gamble Alkenyl- and alkynyl-containing metalloprotease inhibitors
US6297337B1 (en) 1999-05-19 2001-10-02 Pmd Holdings Corp. Bioadhesive polymer compositions
US6312474B1 (en) * 1999-09-15 2001-11-06 Bio-Vascular, Inc. Resorbable implant materials
JP4754155B2 (ja) * 2000-06-30 2011-08-24 ザ プロクター アンド ギャンブル カンパニー 全身の健康の増進
US8283135B2 (en) * 2000-06-30 2012-10-09 The Procter & Gamble Company Oral care compositions containing combinations of anti-bacterial and host-response modulating agents
PT1294383E (pt) * 2000-06-30 2008-10-08 Procter & Gamble Composições orais compreendendo agentes antimicrobianos
JP2004504326A (ja) * 2000-07-18 2004-02-12 レオ・ファーマ・アクティーゼルスカブ マトリックスメタロプロテイナーゼ阻害剤
FR2814950B1 (fr) * 2000-10-05 2003-08-08 Oreal Utilisation d'au moins un extrait d'au moins un vegetal de la famille des ericaceae, dans des compositions destinees a traiter les signes cutanes du vieillissement
US6693099B2 (en) * 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
US6376514B1 (en) 2000-10-17 2002-04-23 The Procter & Gamble Co. Substituted six-membered heterocyclic compounds useful for treating multidrug resistance and compositions and methods thereof
MXPA04004010A (es) 2001-11-01 2004-07-23 Wyeth Corp Acidos hidroxamicos de aril sulfonamida alenicos como inhibidores de tace y metaloproteinasa de matriz.
PE20030701A1 (es) * 2001-12-20 2003-08-21 Schering Corp Compuestos para el tratamiento de trastornos inflamatorios
US6939860B2 (en) * 2002-01-08 2005-09-06 Matthias Rath Composition and method for treatment of neoplastic diseases associated with elevated matrix metalloproteinase activities using catechin compounds
KR20040075092A (ko) 2002-01-18 2004-08-26 레오 파마 에이/에스 매트릭스 메탈로프로테아제 억제제
US7199155B2 (en) 2002-12-23 2007-04-03 Wyeth Holdings Corporation Acetylenic aryl sulfonate hydroxamic acid TACE and matrix metalloproteinase inhibitors
ATE457716T1 (de) 2002-12-30 2010-03-15 Angiotech Int Ag Wirkstofffreisetzung von schnell gelierender polymerzusammensetzung
US7144588B2 (en) 2003-01-17 2006-12-05 Synovis Life Technologies, Inc. Method of preventing surgical adhesions
EP1449538A1 (de) * 2003-02-21 2004-08-25 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Modulation der EGF Rezeptor Signalübertragung durch Hemmung von TACE oder Amphiregulin
US8198445B2 (en) * 2007-03-09 2012-06-12 National University Corporation Nagoya University Phosphoramide compound, method for producing the same, ligand, complex, catalyst and method for producing optically active alcohol
TW201141536A (en) * 2009-12-21 2011-12-01 Colgate Palmolive Co Oral care compositions and methods
WO2013003360A1 (en) * 2011-06-29 2013-01-03 Janssen Pharmaceutica Nv Methods of treatment using allosteric processing inhibitors for matrix metalloproteinases
RU2488587C1 (ru) * 2012-05-23 2013-07-27 Федеральное государственное бюджетное образовательное учреждение высшего профессионального образования "Казанский национальный исследовательский технологический университет" Анилид гидроксиметиланилинометилфосфиновой кислоты (амидофос) в качестве биостимулятора активного ила в процессе очистки сточных вод и способ его получения
SI3364958T1 (sl) 2015-10-23 2023-05-31 Navitor Pharmaceuticals, Inc. Modulatorji interakcije sestrina in gator2 ter njihova uporaba
WO2017117130A1 (en) 2015-12-28 2017-07-06 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells
CN107709288A (zh) * 2016-02-03 2018-02-16 四川海思科制药有限公司 一种磷酰胺衍生物及制备方法和用途
AU2017257185B8 (en) * 2016-04-29 2023-07-06 Ophirex, Inc. Phospholipase A2 inhibitors for immediate treatment of venom toxicity that causes hemolysis, cerebral edema, and acute kidney injury
CN106905183B (zh) * 2017-02-24 2018-07-31 三峡大学 一类含氨基的ɑ-酰氧基羰基酰胺类衍生物，制备方法及其应用
ES3040534T3 (en) * 2017-04-26 2025-11-03 Navitor Pharm Inc Modulator of sestrin-gator2 interaction for use in the treatment of treatment-resistant depression
CA3117336A1 (en) 2018-10-24 2020-04-30 Navitor Pharmaceuticals, Inc. Polymorphs of (s)-2-amino-5,5-difluoro-4,4-dimethylpentanoic acid for use in modulating mtorc1
IL292612A (en) 2019-11-01 2022-07-01 Navitor Pharm Inc Treatment methods using mtorc1 modulator

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4091024A (en) * 1976-12-03 1978-05-23 E. R. Squibb & Sons, Inc. Pyrrolidine and piperidine-2-carboxylic acid derivatives
GB8601368D0 (en) * 1986-01-21 1986-02-26 Ici America Inc Hydroxamic acids
DK77487A (da) * 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
FR2609289B1 (fr) * 1987-01-06 1991-03-29 Bellon Labor Sa Roger Nouveaux composes a activite d'inhibiteurs de collagenase, procede pour les preparer et compositions pharmaceutiques contenant ces composes
GB8827305D0 (en) * 1988-11-23 1988-12-29 British Bio Technology Compounds
GB8919251D0 (en) * 1989-08-24 1989-10-04 British Bio Technology Compounds
DE4011172A1 (de) * 1990-04-06 1991-10-10 Degussa Verbindungen zur bekaempfung von pflanzenkrankheiten
US5189178A (en) * 1990-11-21 1993-02-23 Galardy Richard E Matrix metalloprotease inhibitors
US5183900A (en) * 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
GB9102635D0 (en) * 1991-02-07 1991-03-27 British Bio Technology Compounds
GB9107368D0 (en) * 1991-04-08 1991-05-22 Smithkline Beecham Plc Novel compounds
IL98681A (en) * 1991-06-30 1997-06-10 Yeda Rehovot And Dev Company L Pharmaceutical compositions comprising hydroxamate derivatives for iron removal from mammalian cells and from pathogenic organisms and some novel hydroxamate derivatives
DE4127842A1 (de) * 1991-08-22 1993-02-25 Rhone Poulenc Rorer Gmbh 5-((omega)-arylalky)-2-thienyl alkansaeuren, ihre salze und/oder ihre derivate
JPH05125029A (ja) * 1991-11-06 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアミド化合物又はその塩
EP0634998B1 (de) * 1992-04-07 1997-03-19 British Biotech Pharmaceuticals Limited Hydroxamsäure enthaltende collagenase-inhibitoren und cytokinaktivitätsinhibitoren
WO1993021942A2 (en) * 1992-05-01 1993-11-11 British Biotech Pharmaceuticals Limited Use of mmp inhibitors
AU666727B2 (en) * 1992-06-25 1996-02-22 F. Hoffmann-La Roche Ag Hydroxamic acid derivatives
GB9215665D0 (en) * 1992-07-23 1992-09-09 British Bio Technology Compounds
GB9223904D0 (en) * 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5514716A (en) * 1994-02-25 1996-05-07 Sterling Winthrop, Inc. Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
JPH10501806A (ja) * 1994-06-22 1998-02-17 ブリティッシュ バイオテック ファーマシューティカルズ リミテッド 金属タンパク質分解酵素阻害剤

Also Published As

Publication number Publication date
CN1228780A (zh) 1999-09-15
SK25499A3 (en) 2000-03-13
PE107698A1 (es) 1999-02-11
ATE226590T1 (de) 2002-11-15
IL128668A (en) 2002-02-10
NZ334258A (en) 2000-11-24
HUP9903916A3 (en) 2001-06-28
TW518338B (en) 2003-01-21
DE69716619T2 (de) 2003-06-26
CA2264254C (en) 2003-03-11
CA2264254A1 (en) 1998-03-05
CO4900033A1 (es) 2000-03-27
AU732653B2 (en) 2001-04-26
WO1998008853A1 (en) 1998-03-05
AU4153197A (en) 1998-03-19
CZ63699A3 (cs) 1999-07-14
EP0925303A1 (de) 1999-06-30
ID18145A (id) 1998-03-05
JP3539736B2 (ja) 2004-07-07
NO990857D0 (no) 1999-02-23
US5830915A (en) 1998-11-03
HUP9903916A2 (hu) 2001-05-28
DE69716619D1 (en) 2002-11-28
KR20000035925A (ko) 2000-06-26
EP0925303B1 (de) 2002-10-23
RU2170232C2 (ru) 2001-07-10
DK0925303T3 (da) 2003-02-24
ZA977700B (en) 1998-02-23
IL128668A0 (en) 2000-01-31
BR9713182A (pt) 1999-11-03
TR199900399T2 (xx) 1999-06-21
PL331854A1 (en) 1999-08-16
JP2000515167A (ja) 2000-11-14
AR009357A1 (es) 2000-04-12

Similar Documents

Publication Publication Date Title
NO990857L (no) Fosfinsyreamider som matriks-metallprotease-inhibitorer
NO20002826D0 (no) Hydroksamsyrederivater som matriksmetallprotease (MMO) - inhibitorer
FI965156L (fi) Aryylisulfonamido-substituoidut hydroksaamihapot matriisimetalloproteinaasi-inhibiittoreina
NO972307D0 (no) Matriksmetallproteaseinhibitorer
NO995433D0 (no) Protease-inhibitorer
NO990760D0 (no) 1,4-heterocykliske metallproteaseinhibitorer
NO20006716D0 (no) Proteaseinhibitorer
FI961857A7 (fi) Matriksin metalloproteaasien inhibiittorit
NO974403L (no) Reversible proteasehemmere
ATE264339T1 (de) Serine protease inhibitoren
DK0934259T3 (da) Beta-sulfonamidohydroxamsyrer som matrixmetalloproteinase- og TACE-inhibitorer
NO995435D0 (no) Protease-inhibitorer
NO995434L (no) Proteaseinhibitorer
NO995268D0 (no) Proteaseinhibitorer
NO994103D0 (no) Reverse hydroksamatderivater som metallproteaseinhibitorer
FI960482A7 (fi) Matriksin metalloproteaasien inhibiittorit
DK0937036T3 (da) Substituerede 4-biphenyl-4-hydroxysmørsyrederivater som matrixmetalprotease-inhibitorer
NO20003828D0 (no) 2,3,4,5-Tetrahydro-1H-[1,4]-benzodiazepin-3-hydroksamsyrer som matriks-metalloproteinaseinhibitorer
NO986049D0 (no) Matrise metallproteinase inhibitorer
DK1047665T3 (da) Matrix metalloprotease inhibitorer
ATE205822T1 (de) Substituierte 4-arylbutyrsäurederivate als matrix metalloprotease inhibitoren
HRP970246A2 (en) Substituted oxobutric acids as matrix metalloprotease inhibitors
HK1020965A (en) Phosphinic acid amides as matrix metalloprotease inhibitors
MA26429A1 (fr) Inhibiteurs de protease

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application